Asia Pacific Diabetes Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Doctors often refer diabetes as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond appropriately to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).

Asia-Pacific Diabetes Drugs Market  Segments Size & Growth:

Asia-Pacific diabetes drugs market size is projected to reach approximately $XX billion by the end of 2024 with a CAGR of close to 10.4% from $XX billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rise in some diabetics, Government Initiatives and Complexities in alternative diabetes therapy. However, Cost sensitivity issues, Lack of awareness among people and Regulatory framework issues are thereby hampering the market growth.

Asia-Pacific Diabetes Drugs Market  Segments Share:

Asia-Pacific diabetes drugs market is categorised into Drugs which comprise of Insulin Derivatives and Oral Diabetic Medication Drugs. By Drugs, Oral Diabetic Medication Drugs segment is expected to hold the most significant share in the market. By Geography, China and India are projected to dominate the market with the most significant percentage and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.

Asia-Pacific Diabetes Drugs Market  Trends:

• Novo Nordisk is working on Degludec and DegludecPlus as acceptable long-acting choices. It is longer acting and improves blood glucose levels with a lower risk of hypoglycemia, especially during the nighttime. It will be more accessible and more flexible with dosing, possibly three times weekly. Degludec will also have a U-200 version, which allows more insulin in a reduced volume for those who require large amounts. DegludecPlus has a fixed dose of mealtime (30% Novolog) and basal (70% Degludec) insulin. Novo-Nordisk was filing for FDA approval for this new insulin in January 2012.
• Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Israel’s Ministry of Health had granted the Company approval to initiate an exploratory clinical study of its oral insulin capsule ORMD-0801 in patients with nonalcoholic steatohepatitis (NASH).
• Echo Therapeutics – The Symphony System. It is a non-needle, non-invasive, wireless trans-dermal continuous glucose monitoring system. The Symphony System uses a biosensor without the need to prick the skin since it is trans-dermal (it is an adhesive patch placed on the surface). FDA has approved it and is showing substantial successes in clinical trials. Testing is being done on hospitalised critical care patients who require multiple finger sticks daily.

Asia-Pacific Diabetes Drugs Market  Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• The primary market players, such as
• Novo Nordisk
• Eli Lilly and Company
• Sanofi Aventis
• Takeda Pharmaceuticals
• AstraZeneca